Moderna-Merck Cancer Vaccine Sees Promising Results in Adjuvant Melanoma

Moderna and Merck's collaboration on an mRNA-based cancer vaccine is gaining attention due to positive results in adjuvant melanoma.

The companies' intismeran autogene (mRNA-4157) is being studied across multiple tumor types, raising questions about its clinical potential, commercial opportunity, and valuation.

Bloomberg Intelligence estimates the vaccine's peak sales could reach up to $12 billion by 2040 in a best-case scenario, although this figure is risk-adjusted at around $5.4 billion.